Our team
ASC Therapeutics is a division of Applied StemCell, Inc. with decades of experience in developing and improving gene editing and stem cell technologies. We are a flock of dedicated scientists, with strong belief in gene and cell therapy, the future for treating intractable diseases.
Executive Team
Ruhong Jiang, PhD
Co-founder, President and CEO
-20+ years industrial experience (US and China) in research tool, molecular diagnostic product and drug development, and corporate development
-General manager of MicuRx, China
-Founding members of two biotech companies
-Co-founder of two biotech companies
Oscar Segurado, MD, PhD
Chief Medical Officer
-20+ years pre-clinical, clinical & regulatory experience
-Responsible for Humira clinical development
-Inventor-2007 US Patent
-100+ peer-reviewed publications
Allan L. Shaw
Chief Financial Officer
-20+ years in domestic & international financial transactions
-Closed 11 business development deals (e.g. GSK, Amgen, J&J), up to $600M deal size each transaction
-Closed 11 equity transactions in US ad EU markets
Steve Zhang, PhD
VP, Gene & Cell Therapy
-20 years of biotech experience developing novel technologies and genetic therapies
-Former associate director at Sangamo Therapeutics
-Inventor of multiple patents in the field of gene therapy, gene regulation and genome editing
-Ph.D. in molecular genetics from Washington University
Zoya Gluzman-Poltorak, PhD, MBA
VP, Therapeutic Development
-Over 20 years of executive-level leadership experience, advancing cell, gene and protein therapies from idea through pre-clinical and clinical development in multiple therapeutic areas (Hematology, Immunology, Oncology, Neurology, Dermatology, and Cardiovascular Diseases).
-Former Senior Director of Development and Head of Immuno-Oncology at Neumedicines Inc., Pasadena, CA.
-Former Chief Technology Officer at Gene Grafts Ltd. and Angiogenesis Project Lead at MGVS Ltd., Haifa, Israel.
-Cell and Gene Therapy Consultant and Biforum, Israel.
-PhD in Cell and Molecular Biology and MBA from the Technion, Israel Institute of Technology, Haifa, Israel.
-Co-author of multiple patents and peer-reviewed publications.
Lijing Li
Director, CMC Cell and Gene therapy
-More than 25 years’ experience in research and therapeutics development.
-Proven success in setting up translational medicine platform to bring research into clinic.
-Extensive experience in research, preclinical study, process development, GMP manufacturing, analytical development, and quality control.
-10+ years industrial experience in drug development for gene and cell therapy including autologous and allogeneic CarT and Hematopoietic Stem Cell engineering with lentiviral vector, AAV vector, adenoviral vector, and Zinc Finger Nuclease.
The rest of us!
Board of Advisors
Annette Von Drygalski, MD, PharmD, RMSK
Professor of Clinical Medicine, Director of the Hemophilia and Thrombosis Treatment Center at UCSD
Prof. von Drygalski completed fellowship training in hematology/oncology at UC San Diego School of Medicine. She earned her medical and pharmaceutical doctorates from the Ludwig Maximilian University in Munich, Germany.
*** involved in UniQure clinical trial
Steven Pipe
Professor of Pediatrics and Pathology, Medical Director of the Pediatric Hemophilia and Coagulation Disorders Program at the University of Michigan
Prof. Pipe completed his undergraduate medical training at the University of Toronto, Ontario, Canada, and his pediatric training at McMaster University in Hamilton, Ontario. His pediatric hematology and oncology training was completed at the University of Michigan.
*** PI in UniQure clinical trial, involved in BioMarin clinical trial
Gili Kenet, MD,
Professor and Chair of the Haematology department at the Sackler Medical School, Tel Aviv University
Prof. Kenet received her Medical Degree from the Hebrew University in Jerusalem. She is Director of the Israel National Hemophilia Center in Tel Hashomer, Israel.
*** involved in BioMarin clinical trial
Mark A. Kay, MD, Ph.D.,
Dennis Farrey Family Professor in Department of Pediatrics, Professor of Genetics, Stanford University
Prof. Kay is the Dennis Farrey Family Professor and the Associate Chair for Basic Research in the Department of Pediatrics, Professor of Genetics and the Head of the Division of Human Gene Therapy at the Stanford University’s School of Medicine.
Kimo Stine MD,
Professor of Pediatrics and Medical Director of the Arkansas Center of Bleeding Disorders at Arkansas Children’s Hospital
Prof. Stine graduated from the University of Kansas and completed his pediatric residency at the Kansas University Medical Center in Kansas City, Kansas. He completed his training in Pediatric Hematology Oncology at Duke University.
*** involved in Sangamo and UniQure clinical trials